Glenmark Pharmaceuticals receives UK approval for Winlevi, a groundbreaking topical acne treatment with unique mechanism of ...

Glenmark Pharmaceuticals Ltd, in collaboration with Cosmo Pharmaceuticals N.V., has received approval from the UK Medicines ...

Glenmark Pharmaceuticals and Cosmo Pharmaceuticals have received MHRA approval to market Winlevi, a topical acne treatment ...

Glenmark Pharmaceuticals and Ireland-based Cosmo Pharmaceuticals NV have received approval from the Medicines and Healthcare ...

Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Glenmark Pharmaceuticals Limited (Glenmark), a global ...

Glenmark Pharmaceuticals and Cosmo Pharmaceuticals have received approval from the MHRA for marketing Winlevi, an acne treatment, in the UK. The product, which targets patients aged 12 and older, ...

The Global Market for Acne Drugs was estimated to be worth USD 3616.6 Million in 2023 and is forecast to a readjusted size of USD 4592.8 Million by 2030 with a CAGR of 3.4% during the forecast period ...

Monday said that Glenmark had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi in the United Kingdom. Winlevi is the first topical acne treatment ...

Glenmark Pharmaceuticals and Cosmo Pharmaceuticals have received MHRA approval for Winlevi, a topical treatment for acne vulgaris in the UK. This partnership expands Glenmark's dermatology portfolio.